Last reviewed · How we verify

NPH insulin

Novo Nordisk A/S · FDA-approved active Small molecule Under review Quality 0/100

NPH insulin is a Basal insulin Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Humulin N™, Lilly, Brazil, long-acting insulin, Insuman® Basal Solostar®, Insulin added to or substituted for OA.

NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

NPH insulin, also known as isophane insulin, is an intermediate-acting insulin used to help control blood sugar levels in people with diabetes. It works as an insulin receptor agonist, binding to the insulin receptor to stimulate glucose uptake in cells.

At a glance

Generic nameNPH insulin
Also known asHumulin N™, Lilly, Brazil, long-acting insulin, Insuman® Basal Solostar®, Insulin added to or substituted for OA, NPH
SponsorNovo Nordisk A/S
Drug classBasal insulin
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

NPH (Neutral Protamine Hagedorn) insulin is a suspension of insulin crystals complexed with protamine, which slows insulin absorption and extends its duration of action to 10-16 hours. It mimics the basal insulin secretion of the pancreas, providing steady glucose control between meals and overnight. NPH insulin acts on insulin receptors throughout the body to increase glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NPH insulin

What is NPH insulin?

NPH insulin is a Basal insulin drug developed by Novo Nordisk A/S, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does NPH insulin work?

NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

What is NPH insulin used for?

NPH insulin is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes NPH insulin?

NPH insulin is developed and marketed by Novo Nordisk A/S (see full Novo Nordisk A/S pipeline at /company/novo-nordisk).

Is NPH insulin also known as anything else?

NPH insulin is also known as Humulin N™, Lilly, Brazil, long-acting insulin, Insuman® Basal Solostar®, Insulin added to or substituted for OA, NPH.

What drug class is NPH insulin in?

NPH insulin belongs to the Basal insulin class. See all Basal insulin drugs at /class/basal-insulin.

What development phase is NPH insulin in?

NPH insulin is FDA-approved (marketed).

What are the side effects of NPH insulin?

Common side effects of NPH insulin include Hypoglycemia, Weight gain, Injection site reactions, Lipodystrophy.

What does NPH insulin target?

NPH insulin targets Insulin receptor and is a Basal insulin.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing